Concurrent Chemoradiotherapy

CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.

Concurrent chemoradiotherapy use among patients with stage III non-small cell lung cancer increased significantly following publication of the PACIFIC trial, according to a Dutch study published in JTO Clinical and Research Reports.